BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Alembic Pharmaceuticals Ltd.’s Q2 revenues were in line with our estimates whereas profitability was better than expected.
Revenues grew 17.4% YoY to Rs 1457 crore led by strong growth in Rest of World and active pharmaceutical ingredient segments, which grew 84.1% and 28.9% to Rs 197 crore and Rs 263 crore, respectively.
Additionally, U.S. formulations grew 8% to Rs 582 crore while domestic formulations grew 6.1% to Rs 415 crore.
Ebitda margins improved 259 basis points YoY to 30.4% due to better gross margins and lower other expenditure amid lower promotional, travelling and research and development costs.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR